Sichuan Credit Chemwerth Pharmaceutical Co., Ltd ("CREDIT CHEMWERTH"), an API manufacturing company located in Luzhou city, Sichuan Province, is a Sino-US joint venture established by Sichuan Credit Pharmaceutical Co., Ltd and Chemwerth Inc. on Jul.20, 2007. The current company focuses on R&D and manufacturing of chemical APIs, especially the anti-tumor agents. Products in CREDIT CHEMWERTH are for domestic, as well as international markets as those in USA, and Vecuronium Bromide and Tizanidine Hydrochloride et al. are the main products. CREDIT CHEMWERTH successfully passed SFDA inspection for GMP compliance in Dec. 2007, and will receive foreign customers and FDA approval in the near future. Chemwrth has a proven 25-year history of success in the Chinese API industry. With an office in Shanghai, staffed with the highest-level chemist and regulatory professionals in China, Chemwerth is regards as a company with excellent regulatory and technological capability. With the supports on market development, patent laws, regulatory affairs and technical service from Chemwerth, CREDIT CHEMWERTH will make a great promotion in new product R&D, registration, API manufacturing and cGMP compliance, we can also promote our customer service and optimize new product development protocol. As we can see CREDIT CHEMWERTH will enhance Chemwerth's position to be the leading USA supplier of reliable, high quality APIs, and Chemwerth will provide CREDIT CHEMWERTH the necessary technologies and support to ensure and maintain FDA approved, cGMP compliant, and price competitive API to generic pharmaceutical Customers.